1887
  1. Home
  2. Eurosurveillance
  3. Volume 28, Issue 8, 23/Feb/2023
  4. Article
Rapid communication Open Access
Like 1
Download

Abstract

Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4–5) mRNA vaccine 7–90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4–6 months earlier indicated no significant additional protection (10%; 95% CI: −44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.8.2300105
2023-02-23
2025-05-01
/content/10.2807/1560-7917.ES.2023.28.8.2300105
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/8/eurosurv-28-8-2.html?itemId=/content/10.2807/1560-7917.ES.2023.28.8.2300105&mimeType=html&fmt=ahah

References

  1. Italian National Institute of Health (ISS). EpiCentro. Monitoraggio delle varianti del virus SARS-CoV-2 di interesse in sanità pubblica in Italia – Indagini rapide. [Monitoring of the SARS-CoV-2 variants of interest for public health in Italy – rapid investigations]. Italian. Rome: ISS. [Accessed: 1 Feb 2023]. Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-indagini-rapide
  2. Italian Government, Presidency of the Council of Ministers. Report vaccini anti COVID19. [COVID-19 vaccination report]. Rome: Italian Government; 2020. Italian. Available from: https://www.governo.it/it/dipartimenti/commissario-straordinario-lemergenza-covid-19/15974
  3. Italian National Institute of Health (ISS). COVID-19 integrated surveillance: key national data. Rome: ISS. [Accessed: 1 Feb 2023]. Available from: https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-integrated-surveillance-data
  4. European Centre for Disease Prevention and Control (ECDC). Case definition for coronavirus disease 2019 (COVID-19), as of 3 December 2020. Stockholm: ECDC. [Accessed: 1 Feb 2023]. Available from: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition
  5. World Health Organization (WHO). International guidelines for certification and classification (coding) of COVID-19 as cause of death. Geneva: WHO; 2020. Available from: https://www.who.int/publications/m/item/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death
  6. European Medicines Agency (EMA). Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval. Amsterdam: EMA; 2022. Available from: https://www.aifa.gov.it/documents/20142/1621464/2022.09.13_com-EMA_raccomandazione_vaccino_adattato_Comirnaty_B4-5_EN.pdf
  7. Robert Koch Institute (RKI). STIKO: 24. Aktualisierung der COVID-19-Impfempfehlung. [STIKO: 24th update of the COVID-19 vaccination recmmendations]. Epid Bull. 2022;50. German. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2022/Ausgaben/50_22.pdf?__blob=publicationFile
  8. Vaccination Info Service. Le vaccin contre La Covid-19. [The COVID-19 vaccine]. Paris: Santé publique France. [Accessed: 1 Feb 2023]. French. Available from: https://vaccination-info-service.fr/Les-maladies-et-leurs-vaccins/Covid-19
  9. Sistema Nacional de Salud. Consejo Interterritorial. Actualización de las recomendaciones de vacunación frente a COVID-19 para el otoño-invierno en España. [Update on the recommendations of vaccination against COVID-19 for autumn-winter in Spain]. Madrid: Ministerio de Sanidad. [Accessed: 1 Feb 2023]. Spanish. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/Recomendaciones_vacunacion_Otono_Invierno_Covid.pdf
  10. Italian Medicines Agency (AIFA). Modifica della determina n. DG/153/2022 dell'11 aprile 2022 di inserimento dell'indicazione «seconda dose booster» dei medicinali «Comirnaty» e «Spikevax» nell'elenco dei medicinali ai sensi della legge 23 dicembre 1996, n. 648. (Determina n. DG/301/2022). (22A04093) (GU Serie Generale n.161 del 12-07-2022). [Amendment of resolution no. DG/153/2022 of 11 April 2022 on the inclusion of the indication ”second booster dose” of the medicines ”Comirnaty” and ”Spikevax” in the list of medicines pursuant to the law of 23 December 1996, n. 648. (Decision no. DG/301/2022). (22A04093) (GU General Series n.161 of 12-07-2022)]. Official Gazette of the Italian Republic. 2022;163(161):14. Italian. Available from: https://www.gazzettaufficiale.it/eli/gu/2022/07/12/161/sg/pdf
  11. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;S1473-3099(22)00801-5.  https://doi.org/10.1016/S1473-3099(22)00801-5  PMID: 36681084 
  12. Malato J, Ribeiro RM, Fernandes E, Leite PP, Casaca P, Antunes C, et al. Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months. Lancet Infect Dis. 2023;23(2):148-50.  https://doi.org/10.1016/S1473-3099(22)00833-7  PMID: 36620968 
  13. Hansen CH, Friis NU, Bager P, Stegger M, Fonager J, Fomsgaard A, et al. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark. Lancet Infect Dis. 2023;23(2):167-76.  https://doi.org/10.1016/S1473-3099(22)00595-3  PMID: 36270311 
  14. Italian Ministry of Health. Avvio della somministrazione di dosi “booster” nell’ambito della campagna di vaccinazione anti SARS-CoV-2/COVID-19. [Start of the administration of booster doses as part of the anti-SARS-CoV-2/COVID-19 vaccination campaign]. Rome: Ministero della Salute; 2021. Italian. Available from: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=82953&parte=1%20&serie=null
Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Massimo+Fabiani&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fabiani Massimo</a>, <a href="/search?value1=Alberto+Mateo-Urdiales&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mateo-Urdiales Alberto</a>, <a href="/search?value1=Chiara+Sacco&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sacco Chiara</a>, <a href="/search?value1=Emmanouil+Alexandros+Fotakis&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fotakis Emmanouil Alexandros</a>, <a href="/search?value1=Maria+Cristina+Rota&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rota Maria Cristina</a>, <a href="/search?value1=Daniele+Petrone&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Petrone Daniele</a>, <a href="/search?value1=Marco+Bressi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bressi Marco</a>, <a href="/search?value1=Martina+Del+Manso&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Del Manso Martina</a>, <a href="/search?value1=Andrea+Siddu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Siddu Andrea</a>, <a href="/search?value1=Giorgio+Fedele&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fedele Giorgio</a>, <a href="/search?value1=Paola+Stefanelli&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Stefanelli Paola</a>, <a href="/search?value1=Antonino+Bella&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bella Antonino</a>, <a href="/search?value1=Flavia+Riccardo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Riccardo Flavia</a>, <a href="/search?value1=Anna+Teresa+Palamara&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Palamara Anna Teresa</a>, <a href="/search?value1=Giovanni+Rezza&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rezza Giovanni</a>, <a href="/search?value1=Silvio+Brusaferro&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brusaferro Silvio</a>, <a href="/search?value1=Patrizio+Pezzotti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pezzotti Patrizio</a>, <a href="/search?value1=on+behalf+of+the+Italian+Integrated+Surveillance+of+COVID-19+study+group+and+of+the+Italian+COVID-19+Vaccines+Registry+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the Italian Integrated Surveillance of COVID-19 study group and of the Italian COVID-19 Vaccines Registry group</a></span>. Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022. <a href="/content/ecdc">Euro Surveill.</a> 2023;28(8):pii=2300105. <a href="https://doi.org/10.2807/1560-7917.ES.2023.28.8.2300105" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2023.28.8.2300105</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 12 Feb 2023;&nbsp;&nbsp; <span class="generated">Accepted</span>: 21 Feb 2023 </span> </p>
/content/10.2807/1560-7917.ES.2023.28.8.2300105
/content/10.2807/1560-7917.ES.2023.28.8.2300105
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error